Quantum BioPharma Ltd. (NASDAQ: QNTM) has received U.S. Food and Drug Administration clearance to launch a Phase 2 clinical trial of Lucid-MS, a patented, first-in-class candidate for multiple sclerosis that aims to protect and potentially rebuild the myelin sheath rather than suppress the immune system. The milestone was highlighted in a recent BioMedWire editorial examining the drug’s potential to address limitations of existing MS treatments.
According to the editorial, the upcoming trial would mark the first time a drug based on this mechanism is tested in people living with MS. Current MS therapies primarily focus on modulating or suppressing the immune system to reduce relapses, but they do not directly repair myelin damage, which is the underlying cause of disability progression in many patients. Lucid-MS, developed by Quantum’s wholly owned subsidiary Lucid Psycheceuticals Inc., has shown in preclinical models the ability to prevent and reverse myelin degradation.
The significance of this announcement lies in its potential to shift the treatment paradigm for multiple sclerosis, a chronic, often disabling disease of the central nervous system that affects millions worldwide. If successful, Lucid-MS could offer a disease-modifying approach that not only slows progression but also restores neurological function, a goal that has eluded existing therapies. The FDA’s clearance to proceed with Phase 2 testing represents a critical step in validating this novel mechanism in human patients.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Beyond Lucid-MS, the company invented UNBUZZD™ and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and royalty rights of 7% on sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
For investors, the Phase 2 trial initiation is a key catalyst that could drive value if early human data confirm the preclinical findings. The company’s newsroom at https://ibn.fm/QNTM provides ongoing updates. The full press release can be viewed at https://ibn.fm/whtAF. More information about InvestorWire, the platform that syndicated the editorial, is available at https://www.InvestorWire.com, and terms of use and disclaimers can be found at https://www.InvestorWire.com/Disclaimer.
